Business Context and Reporting Period
This Form 8-K Current Report was filed by Trovagene, Inc. on February 19, 2014. The filing reports corporate governance changes effective as of the report date. Note: The request metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as "Trovagene, Inc."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Appointment of Director: Dr. Rodney S. Markin was appointed as a Director to serve until the next stockholder election. He brings expertise in clinical laboratory automation, robotics, and pathology, having previously founded LAB-InterLink and served as CTO at the University of Nebraska Medical Center.
- Resignation of Director: Dr. Chris McGuigan resigned from the Board of Directors to pursue other opportunities.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. It serves solely to disclose the change in board composition and references a press release issued on the same date.
Key Facts for Investor Verification
- Verify the correct registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the effective date of Dr. Markin's appointment and Dr. McGuigan's resignation (February 19, 2014).
- Review the attached press release (Exhibit 99.1) for additional context on the board changes.
- Note that no financial performance data is included in this specific filing.